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A b s t r a c t  
The objective of the present investigation was to apply statistical design for the development of 
risedronate sodium floating-bioadhesive tablets (RSFBT) employing response surface methodology 
(RSM). A central composite design (CCD) was developed using Design of Expert (DOE) software to 
study the effect of formulation variables on the drug delivery system. The RSFBT were prepared by 
direct compression using hydroxy propyl methyl cellulose (HPMC K100M) as release retardant; 
carbopol (CP 974P) as bioadhesive polymer and sodium bicarbonate (NaHCO3) as a gas-former. 
The quantities of HPMC K100M (X1), CP 974P (X2) and NaHCO3 (X3) were taken as independent 
variables and percentage drug release at 2 h (Q2), 6 h (Q6) and 12 h (Q12), floating lag time (FLT), 
total floating time (TFT) and bioadhesive strength (BS) were selected as responses. The BS was 
determined using porcine gastric mucosa. In all 15 formulations were prepared and studied. The 
results of the CCD indicated that high levels of both X1 and X3, and low level of X2 were required for 
the preparation of RSFBT. Further, a good correlation was observed between predicted and 
experimental values of the independent variables selected for this study. The drug release profiles of 
all the formulations were fitted into zero-order, first-order, Higuchi and Peppas models. The 
optimized formulation followed the Peppas model with a non-Fickian diffusion mechanism. The 
statistically optimized formulation (RSFBTsopt) was found to be physically stable when stored at 40 
μ 2 oC/75 μ 5% RH for 3 months. In vivo evaluation of RSFBTsopt, BaSO4-loaded tablets revealed a 
mean gastric retention time of 5 μ 0.86 h (n=3) in healthy volunteers. 
Keywords: Floating-bioadhesive tablets, Central composite design, Design of Expert, In vitro 
buoyancy, Ex-vivo bioadhesion, In vivo gastric residence time  
 
 
Introduction 
Sustained release (SR) formulations offer several pharmacokinetic 
and pharmacodynamic advantages over conventional dosage 
forms such as maintenance of constant therapeutic levels for 
prolonged period of time and minimize the fluctuations in plasma 
drug concentration. SR formulations might lower the risk of 
treatment failure [1], improve patient compliance by reducing 
dosing frequency and administration of total dose. However, SR 
dosage forms were not only developed to control the drug release 
for a specific period of time but also to prolong the residence time 
of the dosage form in the stomach or proximal part of small 
intestine. The presence of a dosage form in the upper part of 
gastrointestinal tract was important especially for drugs that are 
degraded or metabolised in the intestine or drugs had local action 
in the stomach [2, 3]. Further, for drugs with poor solubility in the 
intestine and those with site-specific absorption limitations, gastric 
retention approach might increase the overall gastrointestinal 
absorption [4]. Approaches to increase the gastric residence time 
of drug delivery systems include bioadhesive systems [5], swelling 
systems that increase their size [6, 7], low density systems [8], 
floating systems [9], high density systems [10], unfoldable and 
expandable systems, magnetic systems, and superporous, 
biodegradable hydrogel systems [11]. 
When the bulk density less than that of gastric fluids, floating drug 
delivery system (FDDS) remains buoyant in the stomach for a 
longer period of time without reducing the gastric emptying rate 
[12]. While the system floats on the gastric contents, the drug is 
released slowly at the desired rate from the system, resulting in an 
increased gastric retention time (GRT) and better control of 
fluctuations in plasma drug levels [13]. The main drawback of 
FDDS is that it is effective only when the fluid level in the stomach 
is sufficiently high. As the stomach empties and the tablet moves 
into the pylorus, which results the buoyancy of the dosage form 
may be retard [14]. This limitation can be overcome by using 
bioadhesive polymers to enable it to adhere to the mucous lining of 
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the stomach wall [15]. Floating- bioadhesive drug delivery systems 
offer the advantages of i) increased contact time with stomach 
mucosa, ii) more effective absorption and bioavailability of drugs 
with absorption window in the stomach and proximal intestine, and 
iii) reduced dosing frequencies [14]. 
Currently, statistical optimization is gaining importance in the 
formulation development. Response surface methodology (RSM) is 
an experimental design in which the factors involved and their 
relative importance can be assessed. RSM permits a deeper 
understanding of a process or product and has important 
applications like optimization and in establishing the robustness of 
the product. Central composite design (CCD) is a progression from 
the factorial designs which have been widely used in RSM and 
optimization [16]. 
Risedronate sodium (RS) is a potent pyridinyl bisphosphonate that 
binds to bone hydroxyapatite and inhibits osteoclast-mediated 
bone resorption. It is a third generation bisphosphonate. In 
preclinical studies risedronate demonstrated potent anti-osteoclast 
and anti-resorptive activity, increasing bone mass and 
biomechanical strength. RS is relatively rapidly absorbed from the 
upper gastrointestinal (GI) tract with a short biological half life of 
1.5 h [17]. No gastroretentive floating-bioadhesive delivery system 
is reported for this drug till now. Due to these characters it is 
considered as a potential candidate for development of floating-
bioadhesive drug delivery system.   
The objective of the present investigation was to apply statistical 
design for the development of risedronate sodium floating-
bioadhesive tablets (RSFBT) employing RSM. CCD was developed 
using Design of Expert (DOE) to study the effect of formulation 
variables on drug release, floating properties, swelling and ex vivo 
bioadhesion study. Physical stability of developed optimized 
formulation at 40 μ 2 oC/75 μ 5% RH for 3 months was studied. 
Further, the optimized formulation was investigated for in vivo 
radiological study to determine the gastric residence time in human 
volunteers. 
Materials and Methods 
Materials 
Risedronate sodium (RS) was received as generous gift sample 
from M/s Hetero Drugs Ltd., Hyderabad, India. Hydroxypropyl 
methyl cellulose (HPMC K100M) was received as gift sample from 
M/s Orchid Pharma Ltd., Chennai, India. Carbopol (CP) 974P was 
received as gift sample from M/s Aurobindo Pharma. Ltd., 
Hyderabad, India. Sodium bicarbonate, microcrystalline cellulose 
(Avicel PH102), magnesium stearate (MS) and talc were 
purchased from S.D. Fine-Chem. Ltd., Mumbai, India. All other 
reagents used were of analytical grade. 
Methods 
Design of experiments 
In this study, a CCD was used to optimize the formulation variables 
of RSFBT containing 3 factors and evaluated at 3 levels. The 
experimental trials were performed at all 15 possible combinations. 
The independent variables in our studies were: quantity of HPMC 
K100M (X1), quantity of CP 974P (X2) and quantity of sodium 
bicarbonate (X3) and for each factor an experimental range was 
selected (Table 1) based on the results of preliminary experiments 
in our laboratory. The amount of MS and talc were kept constant at 
1% w/w, while Avicel PH 102 was used as bulking agent to 
maintain constant tablet weight of 300 mg. The cumulative 
percentage drug released at 2 h (Y1:Q2), 6 h (Y2:Q6) and 12 h 
(Y3:Q12), floating lag time (FLT) in sec, (Y4), total floating time 
(TFT) in hr, (Y5) and bioadhesive strength (BS) in Newton, (Y6) 
were included as responses. The experiments were designed by 
using DOE software (Version 8.0.7.1, Stat-Ease Inc., Minneapolis, 
MN, USA) and the layout of the design is shown in Table 2. The 
DOE software was used to give information not only on the critical 
values required to achieve the desired response but also the 
possible interactions of the selected independent variables on the 
dependent variables. 
 
 
 
 
 Table 1: Independent variables and their levels used in the central composite design. 
 
Independent variables 
 
Levels used, actual (coded) 
Low (-1) Medium (0) High (+1) 
X1:quantity of HPMC K100M (mg) 40 80 120 
X2:quantity of CP 974P (mg) 20 40 60
X3:quantity of NaHCO3 (mg) 30 45 60
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Table 2: Formulations with levels of independent variables and observed responses. 
Formulation Independent variables Responses
X1  
(mg) a 
X2 (mg) 
a 
X3
(mg) a 
Y1
 (%) a 
Y2
(%) a 
Y3
(%) a 
Y4 
(sec) a 
Y5 
(h) a 
Y6
 (N) b 
F1 40 20 30 31.38 50.98 74.53 66.67 12 0.352
F2 120 20 60 31.94 63.4 99.96 25.33 12 1
F3 80 40 19.77 24.79 38.57 52.29 NF NF 0.841
F4 120 20 30 19.78 29.66 45.07 89.67 12 0.96
F5 40 60 30 23.9 36.09 57.17 73.83 5.1 0.625
F6 80 40 70.23 31.19 63.96 99.89 9.67 12 0.922
F7 12.73 40 45 78.53 101.41 101.21 21.5 2 0.35
F8 147.27 40 45 22.55 36.85 54.53 55.5 12 1.114
F9 40 60 60 55.83 98.91 100.91 21.83 7.2 0.6
F10 80 6.36 45 32.76 67.21 100.95 15.67 12 0.568
F11 80 73.64 45 25.85 37 48.2 55.67 8.3 1.138
F12 80 40 45 27.1 43.98 60.13 28.83 12 0.88
F13 40 20 60 36.78 74.45 100.84 26.67 12 0.358
F14 120 60 60 27.96 48.14 62.27 34.17 12 1.278
F15 120 60 30 16.91 24.74 36.43 139.17 8.2 1.217
Independent variables-X1:HPMC K100M, X2:CP 974P and X3:NaHCO3; responses-Y1,Y2 and Y3 were cumulative percentage drug released at 2, 6 and 12 h 
respectively, Y4:FLT, Y5:TFT and Y6:bioadhesive strength. NF: Not floated. 
a Response values: average, n=6; b Response values: average, n=3. 
 
Preparation of risedronate sodium floating-bioadhesive 
tablets 
The experimental tablets were prepared at all possible 
combinations by direct compression. Required quantities of RS, 
HPMC K100M, CP 974P, NaHCO3 and Avicel PH102 were 
weighed individually using electronic balance (AUX220, Shimadzu, 
Japan) and passed through sieve no. 40 to get uniform sized 
particles, then they were taken in a mortar and triturated for 10 min 
with the help of a pestle. Then the mixture was transferred into a 
polyethylene bag and further mixed for 5 min to ensure a 
homogeneous mass. The mixture was lubricated with 1% w/w MS 
and talc for additional 2 min and this lubricated blend was 
compressed into tablets using 8 mm flat- faced round punches 
on16 station punching machine (Riddhi, RDD3 Ahmedabad, India). 
The hardness of the tablets was adjusted to 6 kg/cm2.  
Determination of in vitro buoyancy 
The in vitro buoyancy of RSFBT was determined in six replicates 
using United States Pharmacopoeia (USP) dissolution apparatus ІІ 
(Electrolab, TDT-06T, Mumbai, India) in 900 ml of 0.1 N HCl 
maintained at 37 μ 0.5 ĈC with paddle rotation of 50 rpm [18]. The 
FLT as well as TFT were determined visually. The time taken by 
the tablet to emerge onto surface of dissolution medium and the 
total time, the tablet remained buoyant on fluid surface were noted 
as FLT and TFT, respectively for all the formulations. 
In vitro drug release studies 
The in vitro dissolution of prepared RSFBT was studied in six 
replicates using USP dissolution apparatus II (Electrolab, TDT-06T, 
Mumbai, India). The dissolution medium was 900 ml of 0.1 N HCl 
(pH1.2), temperature was maintained at 37 μ 0.5 oC with a paddle 
rotation at 50 rpm. Five ml of aliquots were withdrawn at 
predetermined time intervals by means of a syringe and 
immediately replaced with 5ml of fresh dissolution medium each 
time. Samples were filtered using membrane filter (0.45 øm) and 
suitably diluted with dissolution medium wherever necessary and 
absorbance of the samples was measured at λ max 261 nm by 
using double beam UV-Visible spectrophotometer (Elico, SL 210, 
India). 
Drug release analysis and kinetics  
The in vitro drug release profiles were subjected to different kinetic 
models to explain the release kinetics for RSFBT. In this study, the 
in vitro drug release profiles were subjected to zero-order [19], first-
order [20], Higuchi [21] and Korsmeyer-Peppas kinetic models [22]. 
The goodness of fit was evaluated using the correlation coefficient 
values (R2). 
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Zero-order: F = K0t; where F is the fraction of drug released at time 
t, and K0 is the zero-order release constant. 
First-order: ln (1îF) = îK1t; where F represents the fraction of drug 
released at time t, and K1 is the first-order release constant. 
Higuchi model: F = KHt1/2; where F represents the fraction of drug 
released at time t, and KH is the Higuchi constant. 
KorsmeyerăPeppas model: F = KPtn; where F represents the 
fraction of drug released at time t, KP is the rate constant and n is 
the release exponent, indicative of the drug release  mechanism. 
Further, the KorsmeyerăPeppas model was employed in the 
analysis of in vitro drug release behavior of these formulations to 
distinguish between competing release mechanisms. If a value of n 
ª 0.5, indicates the Fickian release mechanism. The value of n 
between 0.5 and 1 is an indication of non-Fickian release 
mechanism (both diffusion controlled and swelling controlled). 
When, n º 1, it is case-II transport and this involves polymer 
dissolution and polymeric chain enlargement or relaxation. 
Swelling studies 
The swelling behaviour of the tablets was determined in triplicate 
as per reported method [23]. Initial weight (W0) of the tablets was 
noted individually and placed separately in a glass beaker 
containing 200 ml of 0.1 N HCl, maintained at 37 μ 0.5 oC. At 
regular time intervals, the tablets were removed and the excess 
surface liquid was carefully removed by means of a filter paper. 
The swollen matrix was then reweighed (W1). The percentage 
swelling was calculated by using following equation. 
 
            Percentage swelling ൌ
ሺWଵିW଴ሻ
W଴
ൈ 100 
Ex vivo bioadhesion study 
 The bioadhesive strength of the RSFBT was determined using an 
ultra test (Mecmesin, West Sussex, UK) equipped with a 5-kg load 
cell. The porcine gastric mucosa was obtained from 
slaughterhouse and was stored in phosphate buffer solution prior 
to the bioadhesion study. The mucosal membrane was excised by 
removing the underlying connective tissue and was secured tightly 
to a circular stainless steel adapter of a diameter 2.2 cm provided 
with the equipment. This was fixed to advanced force gauze. The 
RSFBT to be tested was placed over another cylindrical stainless 
steel adaptor of similar diameter and mounted on the platform of 
motorized test stand. The tablet with a backing membrane was 
adhered on to it using a solution of cyanoacrylate adhesive. All 
measurements were conducted at room temperature. During the 
study, 100 μl of 1% w/v mucin solution was used to moisten the 
porcine gastric mucosal membrane [24]. The upper support was 
lowered at a speed of 0.5 mm/s until contact was made with the 
tissue at the predetermined force of 0.5 N for a contact time of 180 
sec. At the end of the contact time upper support was withdrawn at 
a speed of 0.5 mm/s to detach the membrane from the tablet. Data 
collection and calculations were performed using the data plot 
software package of the instrument. The peak detachment force 
(maximum force required in Newton to detach the tablet from the 
mucosa) or bioadhesive strength (BS) was expressed as mean μ 
SD in triplicate of all formulations (Table 2).  
Statistical analysis of the data and validation of the 
model 
In this study, evaluation of the quality of fit of the model was 
performed employing DOE software. Polynomial models including 
linear, interaction and quadratic terms were generated for all the 
response variables using multiple linear regression analysis. The 
best fit model was selected based on comparison of several 
statistical parameters, including the coefficient of determination 
(R2), adjusted R2 and coefficient of variation (CV) provided by DOE 
software. Further, analysis of variance (ANOVA) was used to 
identify significant effects of factors on response regression 
coefficients. The F test and P values were also calculated using the 
software. The relationship between the dependent and 
independent variables was elucidated using response surface plots 
(Contour and 3-D surface). These plots were used to study the 
effect of various factors on the response at a given time and to 
predict the responses of dependent variables at intermediate levels 
of independent variables. Finally, a numerical optimization 
technique (desirability approach) and a graphical optimization 
technique (overlay plots) were used to generate new formulation 
with desired responses. To validate the chosen experimental 
design, the responses of experimental values were quantitatively 
compared with responses of predicted values and percentage 
relative error was calculated. 
Physical stability studies 
Physical stability studies were conducted according to International 
Conference on Harmonization (ICH) guidelines. The statistically 
optimized formulation (RSFBTsopt) was enclosed in polyethylene 
bottle and placed in a desiccator containing saturated sodium 
chloride solution, which provided 75 μ 5% RH. The desiccator was 
stored at 40 μ 2 oC for 3 months [25]. At predetermined time 
intervals, the tablets were examined for hardness, drug content, in 
vitro buoyancy and drug release. Finally, the tablets were tested for 
any statistical difference using the Students paired t-test, the 
differences were considered to be significant at p < 0.05. 
In vivo buoyancy study   
All the ingredients used in this were transparent to x-ray, and 
therefore, to make the optimized tablet formulation (RSFBTsopt) x-
ray opaque, 30 mg of the drug and 12 mg of Avicel PH 102 were 
replaced with barium sulphate (BaSO4) and weight of all other 
ingredients were kept constant so that the final tablet weight 
remained same. This amount was determined experimentally to 
allow x-ray visibility but not to hinder tablet buoyancy. For in vivo 
radiological study, tablets with following composition were 
prepared: 1.66 % drug, 14 % BaSO4, 39.13 % HPMC K100M, 
6.66% carbopol 974P, 20 % NaHCO3, 16.53 % Avicel PH 102, 1% 
magnesium stearate and 1 % talc. The tablets were prepared by 
direct compression method as described previously. 
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The in vivo gastric residence time of GRDDS can be determined by 
a variety of techniques such as x-ray, endoscopy, ԃ-scintigraphy 
[26]. In this work, x-ray technique was used to determine the 
gastric residence time of RSFBT. The protocol of radiological study 
was approved by the Institutional Ethics Committee, University 
College of Pharmaceutical Sciences, Kakatiya University, India. 
Three healthy male volunteers participated after giving an informed 
written consent. The subjects weighed in between 65ă68 kg (66.3 
μ 1.5 kg), in height from 165-167 cm (166 μ 1.0 cm) and in the age 
group of 25-34 years (29 μ 4.5 years). The study was conducted 
under the guidance of an expert radiologist. About 30 min before 
starting the study, the volunteers were fed with low calorie food 
having 100 g bread and 200 ml water. The optimized, BaSO4-
loaded RSFBTsopt was administered orally to every volunteer with 
200 ml of water.  During the study, the subjects were instructed to 
sit, and not allowed to move around and eat. At different time 
intervals like, 1, 2.5, 4.5 and 5.5 h, the volunteers were exposed to 
abdominal x-ray imaging in a standing position. The distance 
between source of x-rays and the subject was kept constant for all 
images. Thus, the observation of the tablet movements could be 
easily noticed [27].  
Results and Discussion 
The tablets were prepared by direct compression and evaluated for 
their physical characters. The tablet weights ranged between 
298.50 μ 7.11 and 303.0 μ 6.75 mg, the hardness varied between 
5.84 μ 0.43 and 6.08 μ 0.34 kg, thickness between 5.56 μ 0.094 
and 5.62 μ 0.057 mm and friability ranged between 0.29 and 0.42 
%. The drug content of all the formulations varied between 98.18 μ 
2.01 and 101.20 μ 1.24 %. Thus, the physical parameters of the 
prepared tablets were within pharmacopoeial limits. 
Determination of in vitro buoyancy 
 FLT (Y4) of all formulations was within the range of 9.67 sec 
lowest is (F6) to 139.17 sec highest is (F15) and the results are 
shown in Table 2. All formulations floated (Y5) in dissolution 
medium for more than 8 h (except F3, F5, F7 and F9), which 
indicated that good matrix integrity during the extended period of 
time. The results showed that as the concentration of X1 increased 
from 12.73 mg in F7 to 147.27 mg/tablet in F8, the FLT (Y4) 
decreased from 55.50 sec in F8 to 21.50 sec in F7 due to the 
increased hydrophilic nature of the polymer allowing penetration of 
water. And the TFT (Y5) increased due to swelling of the tablet, 
which kept it intact for a longer period of time [28]. The 
concentration of X2 also significantly influenced on Y4 and Y5 
responses. As the concentration of X2 increased from 6.36 mg in 
F10 to 73.40 mg/tablet in F11, the Y4 was increased from 15.67 
sec in F10 to 55.67 sec in F11 and Y5 was decreased. Further, the 
X3 also affected Y4 and Y5 responses. As the X3 concentration 
increased from 19.77 mg in F3 to 70.23 mg/tablet in F6, the Y4 was 
decreased from 28.83 sec in F12 to 9.67 sec in F6. Apart from this, 
the formulation F3 could not float on dissolution medium due to 
insufficient gas generated, to keep the tablets floating. In this work, 
NaHCO3 was used as a gas-generating agent in order to aid 
floating of tablets. The NaHCO3 induced CO2 generation in the 
presence of dissolution medium (0.1 N HCl, pH 1.2). The gas 
generated was trapped and protected within the gel formed by 
hydration of the polymer, thus decreasing the density of the tablet 
below 1 gm/ml, leading to tablet buoyancy [29]. 
In vitro drug release studies 
In vitro drug release of all fifteen formulations of RSFBT was 
carried out in 0.1 N HCl (pH 1.2). The study was performed for 12 h 
and drug release profiles are shown in Figure 1.  
 
Figure 1: In vitro dissolution profiles of GFBT of RS A) formulations, F1 to F7 and B) formulations, F8 to F15 (n=6). SD bars are not visible.  
 
Effect of concentration of HPMC K100M The effect of concentration of X1, 12.73 mg, 80 mg and 147.27 
mg/tablet on drug release was evaluated and is shown in Figure 2. 
The maximum cumulative release of RS from the formulation F7 
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containing 12.73 mg/tablet was 100.81 μ 2.19 % at end of 4 h. 
Similarly, drug release from formulations F8 and F12 containing 
147.27 mg and 80 mg/tablet was 54.52 μ 1.19 % and 60.13 μ 0.91 
% respectively at 12 h (Y3). The difference in drug release might be 
due to the amount of gel layer formed around the tablets. At higher 
concentration of X1 resulted in a greater amount of gel being 
formed. This gel increased diffusion length so that drug release 
was decreased. When concentration of X1 was 12.73 mg/tablet, 
the RSFBT could not retain its physical integrity for desired period 
of 12 h. If the physical integrity is not maintained, the tablet would 
break down into smaller fragments and escape from the upper part 
of the GIT [30]. As the concentration of X1 was increased, the 
tablets could retain their physical integrity and the drug release was 
significantly extended. 
 
 
Figure 2: Effect of concentration of HPMC K100M on release of RS 
from GFBT (n=6). SD bars are not visible. 
Effect of concentration of CP 974P  
Carbomer 974P readily absorbs water and swells. In addition to its 
hydrophilic nature, cross-linked structure and insolubility in water 
makes the Carbopol 974P as a potential candidate for use in 
controlled release drug delivery systems. 
The effect of CP 974P (X2) concentration (6.36 mg, 73.64 mg and 
40 mg/tablet) on the release was evaluated (Figure 3). The amount 
of drug released from the formulation F10 containing 6.36 
mg/tablet was 100.94 μ 1.65 % at the end of 12 h (Y3). Similarly, 
48.19 μ 2.36 % and 60.13 μ 0.91 % of drug was released at the 
end of 12 h from formulations F11 and F12 containing 73.64 mg 
and 40 mg/tablet, respectively. Increase in concentration of X2, 
decreased the drug release, which could be due to increased 
imbibition of water into the polymer. Further, Carbopol 974P (X2) 
and HPMC K100M (X1) produce a synergistic increase in viscosity 
due to the stronger hydrogen bonding between these two polymers 
[31]. This in turn formed stronger bridges between the two 
polymers resulting in a more rigid structure, which influenced drug 
diffusion to slow down. 
 
Figure 3: Effect of concentration of CP 974P on release of RS from 
GFBT (n=6). SD bars are not visible. 
Effect of concentration of NaHCO3 
The RSFBT employed NaHCO3 (X3) as gas-forming agent to 
improve in vitro buoyancy. The influence of X3 on cumulative drug 
release was also investigated (Figure 4). The cumulative amount of 
drug released from formulation F3 containing 19.77 mg/tablet was 
found to be 52.28 μ 1.19 % in 12 h (Y4). Whereas, the amount of 
drug released from formulations F6 and F12 containing 70.23 mg 
and 45 mg/tablet was 99.89 μ 1.10 % and 60.13 μ 0.91 % 
respectively in 12 h.  As the concentration of X3 increased from 
19.77 to 70.23 mg/tablet, drug release was significantly increased. 
 
Figure 4: Effect of concentration of NaHCO3 on release of RS from 
GFBT (n=6). SD bars are not visible. 
Drug release analysis and kinetics 
The in vitro drug release profiles of all the RSFBT formulations 
were subjected to different kinetic models. The n value with 
corresponding correlation coefficients (R2) for all the formulations 
are shown in Table 3. Release of the drug from formulations F1, 
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F4, F5, F8, F9 and F15 followed Higuchi model due to high R2 
value (0.909 in F9 to 0.996 in F1) whereas that from F2, F3, F6 
and F10-F14 followed Peppas model and the R2 value ranged from 
0.994 in F12 and F13 to 0.998 in F10 and F11. The value of 
release exponent n for all the RSFBT formulations ranged from 
0.223 in F7 to 0.620 in F10. Release of the drug from formulations 
F2, F6, F10 and F13 involved non-Fickian diffusion (n values 
ranged from 0.596 in F13 to 0.620 in F10) indicated diffusion 
controlled and swelling controlled while those others involved 
Fickian diffusion indicated diffusion controlled. The release rate 
constants (k) of all the RSFBT formulations were significantly 
different. The kp value for all the formulations was ranged from 
13.15 in F15 to 64.71 in F7. Higher the value of k, greater the drug 
released
 
  Table 3: Mathematical models and release kinetics of RS from FBT. 
Formulation Zero order First order Higuchi Korsmeyer-Peppas
R2 k0 R2 k1 R2 KH R2 KP n
F1 0.903 5.20 0.978 0.100 0.996 98.21 0.990 24.37 0.437
F2 0.961 7.65 0.657 0.467 0.989 105.60 0.997 21.82 0.605
F3 0.858 3.58 0.931 0.053 0.990 96.83 0.997 19.36 0.391
F4 0.895 3.09 0.944 0.043 0.991 98.43 0.984 15.10 0.413
F5 0.913 3.92 0.962 0.060 0.986 98.83 0.969 18.07 0.424
F6 0.964 7.62 0.683 0.418 0.988 105.90 0.997 21.42 0.609
F7 0.477 5.71 0.680 0.371 0.755 72.71 0.745 64.71 0.223
F8 0.911 3.82 0.965 0.057 0.995 99.03 0.989 17.06 0.444
 
Swelling studies 
The ability of hydration of the formulation is important because it 
effects on: (a) tablet buoyancy, (ii) adhesion ability of swellable 
polymers and (iii) drug release kinetics. 
The maximum percentage of swelling was observed at the end of 
12 h for all the formulations    (Figure 5). There was a significant (P 
< 0.05) increase in swelling of the tablet containing varying amount 
of X1 (F7, F8 and F12) with an increase in the X1 content. Further, 
the amount of X2 also influenced on tablet swelling. The tablet 
swelling was increased with an increase in X2 content (F10, F11 
and F12). In all the formulations, maximum swelling (344.91μ6.35 
%) was observed for formulation F8 containing 147.27 mg of X1, 40 
mg of X2 and 45 mg of X3.  
 
Figure 5: Effect of concentration of various excipients on swelling of 
GFBT of RS (n=3). 
Ex-vivo bioadhesion study 
Apart from in vitro buoyancy of the tablet, bioadhesive property 
could be an important property for gastroretentive drug delivery 
systems. The developed formulations contained CP 974P, which 
has bioadhesive property. HPMC polymers are also reported to 
have the bioadhesive property. Other materials used in the study 
such as NaHCO3, Avicel pH 102, magnesium stearate and talc do 
not possess bioadhesive properties. The bioadhesive strength (BS) 
of the developed RSFBT is shown in Table 2. The effects of X1 and 
X2 and their interaction on Y6 at a fixed level of X3 are shown in 
Figure 7. At low level of X2, Y6 was found to be increased from 
0.352 N in F1 to 1.0 N in F2 when the concentration of X1 
increased from 40 mg to 120 mg. Similarly, at high levels of X2, the 
response Y6 increased from 0.6 N in F9 to 1.278 N in F14 when X1 
increased from 40 mg to 120 mg. Whereas NaHCO3 (X3) could not 
show any effect on bioadhesion. The minimum Y6 (0.350μ0.026 N) 
was observed for formulation F7 containing 12.73 mg of X1 and 40 
mg of X2. Similarly, formulation F14 showed maximum Y6 
(1.278μ0.046 N), which contained 120 mg of X1 and 60 mg of X2. 
From the results, BS was found to be increased by increasing 
either of the components, HPMC K100M and CP 974P.  
Statistical analysis of the data and validation of the 
model 
The responses of all the formulations were fitted to linear, 
interaction or quadratic models using DOE software. A linear model 
is suggested for Q2, Q6, Q12 and FLT, interaction model for TFT, 
and quadratic model for BS. The calculated R2 (Table 4) values for 
all the responses ranged from 0.7728 to 0.9991 indicating a good 
model. The adjusted and predicted R2 values were 0.7047 and 
0.5215 for Q2, 0.7958 and 0.6759 for Q6, 0.8550 and 0.7859 for 
Q12, 0.7745 and 0.6548 for FLT, 0.8231 and 0.6029 for TFT and 
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0.9971 and 0.9898 for BS respectively. In all the responses, the 
adjusted and predicted R2 values are in reasonable agreement. In 
all the cases, precision values ranged in between 9.8900 and 
67.1819 indicating an adequate signal and the model can be 
navigated within the design space. 
 
  Table 4: Statistical parameters for the responses of RSFBT. 
Parameter Q2   (%) Q6   (%) Q12      (%) FLT (%) TFT (%) Bioadhesive 
strength (N) 
Mean 0.1907 0.1475 70.9407 1.5862 10.5231 -0.2401 
SD 0.0145 0.0127 9.3055 0.1553 1.0188 0.0228 
CV % 7.6131 8.5866 13.1173 9.7932 9.6814 9.5092 
R2 0.7728 0.8429 0.8884 0.8309 0.9116 0.9991 
Adj R2 0.7047 0.7958 0.8550 0.7745 0.8231 0.9971 
Pred R2 0.5215 0.6759 0.7859 0.6548 0.6029 0.9898 
Adeq Precis 9.8900 12.7611 15.7206 10.9105 10.1446 67.1819 
 
The application of RSM yielded the following regression equations. 
 
Y1(Q2)=0.19+0.00044X1+0.00023X2ă0.0011X3        (1) 
Y2(Q6) = 0.16 + 0.00038X1 + 0.00043X2 ă 0.0013X3             (2) 
Y3 (Q12) = 65.94 ă 0.28X1 ă 0.56X2 + 1.12X3               (3) 
Y4 (FLT) =  2.16+0.0018X1 + 0.0044X2 ă 0.019X3           (4) 
Y5 (TFT) = 18.69 ă 0.040X1 ă 0.29X2 ă 0.072X3 + 
 0.0012X1X2 + 0.00035X1X3 + 0.0025X2X3                       (5)                                                                           
Y6 (Bioadhesive strength) = -2.50 + 0.030X1 + 0.02X2 ă 0.00019X3 
ă 0.000095X1X2 + 0.000024X1X3 ă 0.000021X2X3 ă 0.00011X12 ă 
0.000079X22 + 0.0000023X32                        (6)    
                                                                                                                                                                                        
The two-dimensional contour plots and three-dimensional response 
surface plots are shown in Figures 6 and 7. These plots are very 
useful to study the interaction effects of the factors on the 
responses, i.e., two factors on the response at one time. In all the 
presented figures, the third factor was kept at a constant level.  
All the responses were optimized with different targets by a 
multicriteria decision approach (a numerical optimization technique 
by the desirability function and a graphical optimization technique 
by the overlay plot) and are shown in Figures 8 and 9. The 
optimized formulation was obtained by applying constraints on both 
dependent and independent variables. The constraints were: Q2 26 
μ 5 %, Q6 56 μ 5%, Q12 95 μ 5 % (fixed based on theoretical drug 
release profile calculation); minimal FLT; maximal TFT and 
maximal BS. These constrains remained same for all the 
formulations. The recommended constraints of the independent 
variables were calculated by the DOE software. From the above 
plot, the desirability was found to be 0.810. The extensive grid and 
feasibility searches provided the selection of optimum formulation 
by using desired response plot and over lay plot respectively. 
The optimum values of selected independent variables obtained by 
using DOE software were 117.40 mg HPMC K100M (X1), 20 mg 
CP 974P (X2) and 60 mg NaHCO3 (X3). The final optimal tablet 
composition contained 117.40 mg HPMC K100M, 20 mg CP 974P, 
60 mg NaHCO3, 61.60 mg Avicel PH 102, 3 mg magnesium 
stearate and 3 mg talc. The statistically optimized formulation 
(RSFBTsopt) fulfilled all the physicochemical characters and had 
Q2 30.72 %; Q6 61.91 %; Q12 97.25 %; FLT 20.83 s; TFT >12 h 
and BS 0.996 N. Release of the drug from RSFBTsopt followed 
Peppas model (R2 = 0.996) with non-Fickian diffusion mechanism 
(n = 0.607 and Kp = 21.08). The observed responses of 
RSFBTsopt were in close agreement with the model predictions 
and the relative errors (%) was calculated (Table 5). The 
experimental values were in agreement with the predicted values 
confirming the predictability and validity of the model. 
Physical stability studies 
The RSFBTsopt was selected for stability studies. Before and after 
conducting the stability studies for 3 months, the results were 
analysed by using StudentÊs paired t-test. No significant difference 
(p > 0.05) was observed in the tablet hardness, drug content, in 
vitro buoyancy or in vitro dissolution (Table 6). Therefore, the 
RSFBTsopt was found to be stable for at least 3 months under 
these storage conditions. 
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